Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients n...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2018-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/315443 |
| _version_ | 1797207565131579392 |
|---|---|
| author | Martina Bogeljić Patekar Vibor Milunović Karla Mišura Jakobac Dražen Perica Inga Mandac Rogulj Marin Kursar Ana Planinc-Peraica Slobodanka Ostojić Kolonić |
| author_facet | Martina Bogeljić Patekar Vibor Milunović Karla Mišura Jakobac Dražen Perica Inga Mandac Rogulj Marin Kursar Ana Planinc-Peraica Slobodanka Ostojić Kolonić |
| author_sort | Martina Bogeljić Patekar |
| collection | DOAJ |
| description | The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fit for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in first line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regimen has also shown efficacy in relapsed setting suggesting the possible treatment option for patients failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study exploring the addition of obinutuzumab to bendamustine has yielded impressive result changing the standard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of care in young fit patients, as defined in CLL10 study, B-R has yielded a more beneficial toxicity profile and its use in first line treatment should be decided individually. In relapsed setting, the addition of ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation. |
| first_indexed | 2024-04-24T09:24:56Z |
| format | Article |
| id | doaj.art-a532d7dede5040d49da04c819b38aa99 |
| institution | Directory Open Access Journal |
| issn | 0353-9466 1333-9451 |
| language | English |
| last_indexed | 2024-04-24T09:24:56Z |
| publishDate | 2018-01-01 |
| publisher | Sestre Milosrdnice University hospital, Institute of Clinical Medical Research |
| record_format | Article |
| series | Acta Clinica Croatica |
| spelling | doaj.art-a532d7dede5040d49da04c819b38aa992024-04-15T15:17:30ZengSestre Milosrdnice University hospital, Institute of Clinical Medical ResearchActa Clinica Croatica0353-94661333-94512018-01-0157.3.54255310.20471/acc.2018.57.03.18Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic LeukemiaMartina Bogeljić Patekar0Vibor Milunović1Karla Mišura Jakobac2Dražen Perica3Inga Mandac Rogulj4Marin Kursar5Ana Planinc-Peraica6Slobodanka Ostojić Kolonić7Division of Hematology, Merkur University Hospital, Zagreb, CroatiaDivision of Hematology, Merkur University Hospital, Zagreb, Croatia; Lombardi Comprehensive Cancer Centre, Georgetown University, Washington. D.C., United States of AmericaDivision of Hematology, Merkur University Hospital, Zagreb, CroatiaSchool of Medicine, University of Zagreb, Zagreb, CroatiaDivision of Hematology, Merkur University Hospital, Zagreb, CroatiaDivision of Hematology, Merkur University Hospital, Zagreb, CroatiaDivision of Hematology, Merkur University Hospital, Zagreb, Croatia; Lombardi Comprehensive Cancer Centre, Georgetown University, Washington. D.C., United States of AmericaDivision of Hematology, Merkur University Hospital, Zagreb, Croatia; Lombardi Comprehensive Cancer Centre, Georgetown University, Washington. D.C., United States of AmericaThe aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fit for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in first line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting. B-R regimen has also shown efficacy in relapsed setting suggesting the possible treatment option for patients failing conventional chemotherapy. In rituximab-resistant NHL, the recent GADOLIN study exploring the addition of obinutuzumab to bendamustine has yielded impressive result changing the standard of care in this hard-to-treat population. Concerning CLL, despite inferiority to the standard of care in young fit patients, as defined in CLL10 study, B-R has yielded a more beneficial toxicity profile and its use in first line treatment should be decided individually. In relapsed setting, the addition of ibrutinib to B-R has shown superior results compared to B-R alone, possibly changing the paradigm of treatment of relapsed CLL. In conclusion, bendamustine as a single agent or in combinations has shown activity with acceptable toxic profile in the treatment of patients with indolent NHLs or CLL without del(17p) mutation.https://hrcak.srce.hr/file/315443Bendamustine hydrochlorideAlkylating agentsLymphoma, non-HodgkinRituximabLeukemia, lymphocytic, chronic, B-cellObinutuzumab |
| spellingShingle | Martina Bogeljić Patekar Vibor Milunović Karla Mišura Jakobac Dražen Perica Inga Mandac Rogulj Marin Kursar Ana Planinc-Peraica Slobodanka Ostojić Kolonić Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Acta Clinica Croatica Bendamustine hydrochloride Alkylating agents Lymphoma, non-Hodgkin Rituximab Leukemia, lymphocytic, chronic, B-cell Obinutuzumab |
| title | Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia |
| title_full | Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia |
| title_fullStr | Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia |
| title_full_unstemmed | Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia |
| title_short | Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia |
| title_sort | bendamustine an old drug in the new era for patients with non hodgkin lymphomas and chronic lymphocytic leukemia |
| topic | Bendamustine hydrochloride Alkylating agents Lymphoma, non-Hodgkin Rituximab Leukemia, lymphocytic, chronic, B-cell Obinutuzumab |
| url | https://hrcak.srce.hr/file/315443 |
| work_keys_str_mv | AT martinabogeljicpatekar bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT vibormilunovic bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT karlamisurajakobac bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT drazenperica bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT ingamandacrogulj bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT marinkursar bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT anaplanincperaica bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia AT slobodankaostojickolonic bendamustineanolddrugintheneweraforpatientswithnonhodgkinlymphomasandchroniclymphocyticleukemia |